Summary: A major genetic analysis clarifies the potential role of the immune system in schizophrenia.
Source: Lancaster University.
New analysis of the largest schizophrenia genetic dataset to date clarifies how immune-related genes relate to the disorder.
Researchers using data from the largest genome-wide association study (GWAS) of schizophrenia investigated whether genetic variation affecting immune function contributes substantially to the illness. While previous work and clinical observations had raised the possibility that schizophrenia could be an autoimmune disorder—similar to multiple sclerosis, Crohn’s disease, or rheumatoid arthritis—this international team led by Dr Jennie Pouget (University of Toronto) and Dr Jo Knight (Lancaster University) report evidence that the genetic architecture of schizophrenia differs from that of classic autoimmune diseases.
The team specifically tested whether immune genes outside of the major histocompatibility complex (MHC) region are enriched among schizophrenia-associated loci. Although the MHC region has consistently shown strong association with schizophrenia in prior GWAS analyses, global pathway analyses across the genome have produced inconsistent results about immune involvement. In this study, researchers compared schizophrenia’s genetic signal with that of five confirmed autoimmune diseases and found a contrasting pattern.
Of 108 genomic regions previously associated with schizophrenia, the authors identified only six candidate genes (DPP4, HSPD1, EGR1, CLU, ESAM, NFATC3) that have immune-related annotations. Importantly, each of these six genes also has known roles in brain development, neuronal function, or cellular processes unrelated to classical immune signaling. This suggests these genes may exert pleiotropic effects—simultaneously influencing immune biology and neural function—rather than indicating that schizophrenia is predominantly an autoimmune condition.
Lead author Jennie Pouget emphasized that these findings do not rule out any immune involvement, but they argue against schizophrenia being driven primarily by inherited immune dysfunction in the same way that established autoimmune disorders are. Instead, the genetic data point toward a more nuanced picture in which a small subset of genes with dual roles could affect brain development and plasticity while also being connected to immune processes.
Co-author Jo Knight noted the important contribution of environmental factors. For example, epidemiological studies have shown an increased risk of schizophrenia following severe infections requiring hospitalization. Such observations support a model where environmental exposures—such as infection during fetal development or major infections and stress later in life—may activate the immune system and influence brain development or disease progression. Whether immune disturbances are a cause of schizophrenia, a consequence of the disorder, or both remains an open question that requires further investigation.
The study therefore concludes that, based on current genetic evidence, schizophrenia does not appear to be an autoimmune disease in the classical sense. Rather, the disorder’s relationship with immune processes may reflect environmental triggers that recruit immune responses, pleiotropic effects of a small number of genes, or downstream consequences of illness. These distinctions matter for clinical strategies and for the growing interest in testing immunotherapies for psychiatric disorders: genetic data suggest caution in assuming that broad immunomodulation will target the core genetic causes of schizophrenia.
Source: Lancaster University
Image Source: This image is adapted from the Lancaster University press release.
Original Research: Full open-access research article titled “Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases” by Jennie G. Pouget, Vanessa F. Gonçalves, the Schizophrenia Working Group of the Psychiatric Genomics Consortium, Sarah L. Spain, Hilary K. Finucane, Soumya Raychaudhuri, James L. Kennedy, and Jo Knight, published in Schizophrenia Bulletin.
Genome-Wide Association Studies Suggest Limited Immune Gene Enrichment in Schizophrenia Compared to 5 Autoimmune Diseases
This study evaluated whether variation in immune-related genes contributes to schizophrenia susceptibility by analyzing the largest available schizophrenia GWAS dataset and comparing immune gene enrichment with that seen in five diseases of known immune origin. Although the major histocompatibility complex (MHC) remains the most prominent associated region in schizophrenia GWAS, there was no widespread enrichment of immune loci outside the MHC in schizophrenia, in contrast to the clear enrichment observed in the five autoimmune disorders. Among 108 genomic regions previously linked to schizophrenia, six immune candidates were identified, each encoding proteins with additional, nonimmune functions in the brain. These findings suggest that inherited alterations in immune function are unlikely to be a major driver of schizophrenia risk overall. Instead, a limited set of genes with pleiotropic roles in both immune regulation and neural development may help explain observed links between immune markers and the disorder. The results emphasize the need for further research to determine whether immune alterations contribute to schizophrenia progression and whether targeted immunotherapies could benefit specific patient subgroups.
The research provides genetic evidence clarifying the relationship between immune processes and schizophrenia, highlights the potential role of environmental triggers such as infection or stress, and recommends careful, targeted follow-up studies to evaluate immune mechanisms and therapeutic implications. Feel free to share this summary in your own communications or reporting.